Septic Shock Clinical Trial
Official title:
Effects of Dobutamine on Microcirculation, Regional and Peripheral Perfusion in Septic Shock Patients.
The investigators hypothesize that dobutamine is able to revert negative redistribution of
flow by inducing a selective vasodilatory effect on hypoperfused territories, particularly
at the sublingual and gastric mucosa, and at the peripheral tissues.
The investigators designed a randomized, cross-over, placebo-controlled study looking at the
acute physiologic effects of 5 mcg/kg/min fixed-dose of dobutamine on cardiac function,
microcirculation, gastric mucosal, hepatosplanchnic, and peripheral perfusion in septic
shock patients.
The investigators hypothesize that dobutamine is able to revert negative redistribution of
flow by inducing a selective vasodilatory effect on hypoperfused territories, particularly
at the sublingual and gastric mucosa, and at the peripheral tissues. Therefore, dobutamine
improves microcirculatory alterations and regional perfusion in septic shock, independent of
its effects on cardiac output.
The relevance of this concept is that it would support a more rational use of dobutamine in
septic shock patients, not only as an inotrope to increase cardiac output, but more
important, as a selective vasodilator aimed at restoring perfusion.
Therefore, the investigators designed a randomized, cross-over, placebo-controlled study
looking at the acute physiologic effects of 5 mcg/kg/min fixed-dose of dobutamine on cardiac
function, microcirculation, gastric mucosal, hepatosplanchnic, and peripheral perfusion in
septic shock patients.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03649633 -
Vitamin C, Steroids, and Thiamine, and Cerebral Autoregulation and Functional Outcome in Septic Shock
|
Phase 1/Phase 2 | |
| Terminated |
NCT04117568 -
The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
|
||
| Completed |
NCT04227652 -
Control of Fever in Septic Patients
|
N/A | |
| Completed |
NCT05629780 -
Temporal Changes of Lactate in CLASSIC Patients
|
N/A | |
| Recruiting |
NCT04796636 -
High-dose Intravenous Vitamin C in Patients With Septic Shock
|
Phase 1 | |
| Terminated |
NCT03335124 -
The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock
|
Phase 4 | |
| Recruiting |
NCT04005001 -
Machine Learning Sepsis Alert Notification Using Clinical Data
|
Phase 2 | |
| Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
| Recruiting |
NCT05066256 -
LV Diastolic Function vs IVC Diameter Variation as Predictor of Fluid Responsiveness in Shock
|
N/A | |
| Not yet recruiting |
NCT05443854 -
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
|
Phase 3 | |
| Not yet recruiting |
NCT04516395 -
Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae
|
N/A | |
| Recruiting |
NCT02899143 -
Short-course Antimicrobial Therapy in Sepsis
|
Phase 2 | |
| Recruiting |
NCT02565251 -
Volemic Resuscitation in Sepsis and Septic Shock
|
N/A | |
| Recruiting |
NCT02580240 -
Administration of Hydrocortisone for the Treatment of Septic Shock
|
N/A | |
| Recruiting |
NCT02676427 -
Fluid Responsiveness in Septic Shock Evaluated by Caval Ultrasound Doppler Examination
|
||
| Terminated |
NCT02335723 -
ASSET - a Double-Blind, Randomized Placebo-Controlled Clinical Investigation With Alteco® LPS Adsorber
|
N/A | |
| Not yet recruiting |
NCT02547467 -
TOADS Study: TO Assess Death From Septic Shock.
|
N/A | |
| Completed |
NCT02638545 -
Hemodynamic Effects of Dexmedetomidine in Septic Shock
|
Phase 3 | |
| Completed |
NCT02204852 -
Co-administration of Iloprost and Eptifibatide in Septic Shock Patients
|
Phase 2 | |
| Completed |
NCT02306928 -
PK Analysis of Piperacillin in Septic Shock Patients
|
N/A |